Ken Griffin’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-107,600
| Closed | -$1.27M | – | 13787 |
|
|
2025
Q4 | $1.27M | Sell |
107,600
-147,600
| -58% | -$1.59M | ﹤0.01% | 6891 |
|
|
2025
Q3 | $1.97M | Buy |
255,200
+75,300
| +42% | +$527K | ﹤0.01% | 6096 |
|
|
2025
Q2 | $1.32M | Buy |
179,900
+129,300
| +256% | +$1.04M | ﹤0.01% | 6509 |
|
|
2025
Q1 | $480K | Sell |
50,600
-24,400
| -33% | -$305K | ﹤0.01% | 8559 |
|
|
2024
Q4 | $1.24M | Buy |
75,000
+52,300
| +230% | +$812K | ﹤0.01% | 6585 |
|
|
2024
Q3 | $335K | Sell |
22,700
-600
| -3% | -$9.39K | ﹤0.01% | 9093 |
|
|
2024
Q2 | $323K | Sell |
23,300
-53,000
| -69% | -$751K | ﹤0.01% | 8988 |
|
|
2024
Q1 | $1.2M | Buy |
76,300
+1,700
| +2% | +$26.2K | ﹤0.01% | 6559 |
|
|
2023
Q4 | $1.21M | Buy |
74,600
+17,200
| +30% | +$281K | ﹤0.01% | 6308 |
|
|
2023
Q3 | $706K | Buy |
57,400
+3,900
| +7% | +$58K | ﹤0.01% | 7319 |
|
|
2023
Q2 | $860K | Buy |
53,500
+13,300
| +33% | +$219K | ﹤0.01% | 6771 |
|
|
2023
Q1 | $700K | Sell |
40,200
-4,600
| -10% | -$65.5K | ﹤0.01% | 7572 |
|
|
2022
Q4 | $414K | Sell |
44,800
-10,100
| -18% | -$94.2K | ﹤0.01% | 8633 |
|
|
2022
Q3 | $473K | Buy |
54,900
+1,300
| +2% | +$12.9K | ﹤0.01% | 8576 |
|
|
2022
Q2 | $437K | Sell |
53,600
-18,900
| -26% | -$180K | ﹤0.01% | 8949 |
|
|
2022
Q1 | $881K | Buy |
72,500
+12,700
| +21% | +$267K | ﹤0.01% | 7994 |
|
|
2021
Q4 | $2.04M | Buy |
59,800
+35,700
| +148% | +$1.4M | ﹤0.01% | 6183 |
|
|
2021
Q3 | $1.16M | Buy |
24,100
+300
| +1% | +$13.9K | ﹤0.01% | 7768 |
|
|
2021
Q2 | $1.07M | Sell |
23,800
-4,400
| -16% | -$195K | ﹤0.01% | 8190 |
|
|
2021
Q1 | $1.36M | Sell |
28,200
-13,600
| -33% | -$708K | ﹤0.01% | 7357 |
|
|
2020
Q4 | $2.25M | Buy |
41,800
+14,300
| +52% | +$646K | ﹤0.01% | 5111 |
|
|
2020
Q3 | $1.01M | Sell |
27,500
-16,800
| -38% | -$625K | ﹤0.01% | 6004 |
|
|
2020
Q2 | $1.37M | Sell |
44,300
-62,000
| -58% | -$1.72M | ﹤0.01% | 5242 |
|
|
2020
Q1 | $2.94M | Buy |
106,300
+79,400
| +295% | +$2.38M | ﹤0.01% | 3496 |
|
|
2019
Q4 | $787K | Sell |
26,900
-4,900
| -15% | -$117K | ﹤0.01% | 6030 |
|
|
2019
Q3 | $608K | Buy |
31,800
+21,100
| +197% | +$495K | ﹤0.01% | 6430 |
|
|
2019
Q2 | $235K | Buy |
+10,700
| New | +$235K | ﹤0.01% | 7956 |
|
|
2016
Q1 | – | Sell |
-1,100
| Closed | -$9K | – | 7566 |
|
|
2015
Q4 | $9K | Buy |
+1,100
| New | +$8.06K | ﹤0.01% | 8306 |
|
Other funds holding NEO
FLAM
GF
VPM
VCM
B
Ken Griffin's NEO Position: Q1 2026 in Review
Ken Griffin reduced its NeoGenomics (NEO) stake by 80% in Q1 2026, selling an estimated $11M and leaving 263,745 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #6108.
Ken Griffin first reported a position in NEO in Q3 2013 and has held it in 47 quarters since. The position peaked at $24.7M in Q1 2023. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.
- Ken Griffin held 263,745 shares of NeoGenomics worth $1.96M as of Q1 2026.
- Ken Griffin sold 1,043,726 NeoGenomics shares in Q1 2026, an estimated $11M.
- NeoGenomics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6108 holding.
- Ken Griffin first reported a position in NeoGenomics in Q3 2013 and has held it in 47 quarters since.
- Ken Griffin's NeoGenomics position peaked at $24.7M in Q1 2023.
- 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.